Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cabaletta Bio ( (CABA) ) has shared an announcement.
On February 18, 2025, Cabaletta Bio announced new and updated clinical data from its trials involving resecabtagene autoleucel (rese-cel) in the RESET program. Significant findings include promising results for patients with conditions such as dermatomyositis, systemic lupus erythematosus, and systemic sclerosis. The trials showed potential for drug-free remission and improved clinical responses off immunosuppressants and steroids. Cabaletta’s trials aim to evaluate rese-cel’s safety and efficacy, with positive initial outcomes suggesting potential transformative impacts for autoimmune disease treatments.
More about Cabaletta Bio
Cabaletta Bio, Inc. operates within the biotechnology sector, focusing on developing targeted cell therapies for autoimmune diseases. The company is advancing its RESET clinical development program, which includes several Phase 1/2 trials in therapeutic areas like rheumatology, neurology, and dermatology.
YTD Price Performance: 16.31%
Average Trading Volume: 2,598,239
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $132.5M
See more data about CABA stock on TipRanks’ Stock Analysis page.
